Is Orforglipron legal in North Carolina?
status · caveats apply
FDA-approved oral GLP-1 (Foundayo, April 1, 2026) under National Priority Voucher Program; first oral small-molecule GLP-1. No state-level peptide restrictions beyond federal law in North Carolina.
category: investigational · last verified May 13, 2026
§ 01
Quick answer
FDA-approved oral GLP-1 (Foundayo, April 1, 2026) under National Priority Voucher Program; first oral small-molecule GLP-1. No state-level peptide restrictions beyond federal law in North Carolina.
§ 02
Full status breakdown
Federal status
FDA approval
investigational · brand: Foundayo · approved Apr 1, 2026
Indications: chronic weight management in adults with obesity or overweight with weight-related comorbidity
DEA scheduling
not scheduled
503A compounding
Bulks list: not on list
Do-not-compound list: not on list
Approved drug; not a §503A candidate.
FDA Warning Letters
none on record for this compound
Shortage status
not currently on shortage list
Sale framing
Research-use-only posture: As an approved drug, 'research peptide' sales would be unapproved diversion + FDCA violation. No warning letters yet (new approval).
Personal possession: Not federally criminalized; controlled by prescription via LillyDirect.
North Carolina — state-specific
Sport-body status
WADA 2026
USADA
banned
NCAA
unknown
What we couldn’t verify
§ 03
Also known as
Orforglipron is also marketed or referenced under the following names (vendor pseudonyms, brand names, chemical identifiers):
LY3502970FoundayoEli Lilly oral GLP-1OGP
§ 04
Disclaimer
§ 05
Related
- Back to peptide legality lookup — pick a different compound or state
- Peptide pricing index — what each compound costs per mg across audited vendors
- Janoshik COA verifier — a separate question from legality: does the COA the vendor cites actually exist?
the roundup · monthly
Receipts in your inbox. Once a month.
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.
14,200 subscribers· 0 sponsored items· 11 issues since launch